314 related articles for article (PubMed ID: 12599600)
1. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
2. Benign prostatic hypertrophy: update on drug therapy.
Tejani A; Musini V; Perry TL; Mintzes B; Wright JM
Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217
[No Abstract] [Full Text] [Related]
3. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
4. [5alpha-dihydrotestosterone (DHT)].
Komiya A; Suzuki H; Ichikawa T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():452-6. PubMed ID: 16149549
[No Abstract] [Full Text] [Related]
5. Finasteride for benign prostatic hyperplasia.
Hasinski S; Miller JL; Rose LI
Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
[TBL] [Abstract][Full Text] [Related]
6. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
7. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
8. [Drug treatment of benign prostatic hyperplasia].
Schmid HP
Praxis (Bern 1994); 1995 Sep; 84(39):1061-2. PubMed ID: 7481307
[No Abstract] [Full Text] [Related]
9. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
10. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
Hsieh JT; Chen SC; Yu HJ; Chang HC
Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
[TBL] [Abstract][Full Text] [Related]
11. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
Hill M; Petrik R; Hampl R; Stárka L
Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
[TBL] [Abstract][Full Text] [Related]
12. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
13. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
14. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
15. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
[No Abstract] [Full Text] [Related]
16. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of prostate cancer.
Walsh PC
N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
[No Abstract] [Full Text] [Related]
18. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of benign prostatic hyperplasia.
Schmidt JD
West J Med; 1991 Dec; 155(6):633. PubMed ID: 1725942
[No Abstract] [Full Text] [Related]
20. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
